Skip to main content
SpringerLink
Log in
Book cover

Liver Immunology pp 27–43Cite as

The Geoepidemiology of Autoimmune Liver Disease

  • Chapter
  • First Online:

  • 2472 Accesses

Abstract

The liver plays a pivotal role not only in the induction of the immune response against pathogens, but also in the maintenance of tolerance against self-molecules, being one of the largest lymphoid organs [1]. It is therefore not surprising that the liver may be targeted by a tissue-specific inflammatory process as observed in primary liver autoimmune diseases, namely autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Primary immune diseases of the liver are characterized by peculiar histopathology and progressive courses, while virtually all rheumatologic diseases can affect the liver. A clinically significant liver involvement is rare; conversely, liver enzyme abnormalities may be observed in up to half of rheumatology patients. In most cases, a liver biopsy will only demonstrate minor changes and the biochemical findings can be ascribed to the primary affection, while in a small number of patients with rheumatic diseases an overlap syndrome with a coexisting primary liver disease can be diagnosed. In this setting the liver damage is usually progressive, frequently complicated by cirrhosis and portal hypertension. It should, however, be reminded that the most frequent cause of biochemical liver abnormalities among rheumatic patients is provided by medication-induced hepatotoxicity. This chapter is designed to review the wide spectrum of liver involvement that can be seen in the clinical management of patients with extrahepatic autoimmune diseases, but we are convinced that a preliminary discussion of the incidence and prevalence of PBC, PSC, and AIH is a necessary step to understand and manage rheumatological comorbidities in clinical practice [2, 3]. While autoantibodies have different roles in the three conditions, the histological pattern is quite specific, and liver biopsy is a key point for the diagnosis of difficult cases, albeit not recommended in all patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Selmi C, Mackay IR, Gershwin ME. The immunological milieu of the liver. Semin Liver Dis. 2007;27:129–39.

    PubMed  CAS  Google Scholar 

  2. EASL. Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.

    Google Scholar 

  3. Leung PS, Coppel RL, Gershwin ME. Etiology of primary biliary cirrhosis: the search for the culprit. Semin Liver Dis. 2005;25:327–36.

    PubMed  Google Scholar 

  4. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–5.

    PubMed  CAS  Google Scholar 

  5. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865–70.

    PubMed  CAS  Google Scholar 

  6. Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:701–12.

    PubMed  Google Scholar 

  7. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–8.

    PubMed  Google Scholar 

  8. Watson RG, Angus PW, Dewar M, Goss B, Sewell RB, Smallwood RA. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut. 1995;36:927–30.

    PubMed  CAS  Google Scholar 

  9. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470–5.

    PubMed  Google Scholar 

  10. Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, Hilsden RJ, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology. 2009;50:1884–92.

    PubMed  Google Scholar 

  11. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;12:98–105.

    PubMed  CAS  Google Scholar 

  12. Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol. 2010;24:225–31.

    PubMed  Google Scholar 

  13. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14:3374–87.

    PubMed  CAS  Google Scholar 

  14. Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology. 2007;45:659–65.

    PubMed  CAS  Google Scholar 

  15. Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008;14:3328–37.

    PubMed  CAS  Google Scholar 

  16. Selmi C, Diana A, Cocchi CA, Zuin M, Gershwin ME. Environmental factors and the induction of autoimmunity in primary biliary cirrhosis. Expert Rev Clin Immunol. 2008;4:239–45.

    PubMed  CAS  Google Scholar 

  17. Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436–42.

    PubMed  CAS  Google Scholar 

  18. Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M. Is autoimmunity a matter of sex? Autoimmun Rev. 2008;7:626–30.

    PubMed  CAS  Google Scholar 

  19. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010;10:720–6.

    PubMed  CAS  Google Scholar 

  20. Bogdanos DP, Smyk DS, Rigopoulou EI, Mytilinaiou MG, Heneghan MA, Selmi C, Gershwin ME. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun. 2012;38:J156–69.

    PubMed  Google Scholar 

  21. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485–92.

    PubMed  Google Scholar 

  22. Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009;30:415–20.

    PubMed  CAS  Google Scholar 

  23. Selmi C, Zuin M, Gershwin ME. The unfinished business of primary biliary cirrhosis. J Hepatol. 2008;49:451–60.

    PubMed  Google Scholar 

  24. Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Ghosh K, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46:785–92.

    PubMed  Google Scholar 

  25. Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012;2012:610504.

    PubMed  Google Scholar 

  26. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39:34–42.

    PubMed  CAS  Google Scholar 

  27. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28:1–6.

    PubMed  CAS  Google Scholar 

  28. Invernizzi P, Pasini S, Selmi C, Miozzo M, Podda M. Skewing of X chromosome inactivation in autoimmunity. Autoimmunity. 2008;41:272–7.

    PubMed  CAS  Google Scholar 

  29. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, Zuin M, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46:456–62.

    PubMed  CAS  Google Scholar 

  30. Selmi C, Brunetta E, Raimondo MG, Meroni PL. The X chromosome and the sex ratio of autoimmunity. Autoimmun Rev. 2012;11:A531–7.

    PubMed  CAS  Google Scholar 

  31. Selmi C. The X, in sex: how autoimmune diseases revolve around sex chromosomes. Best Pract Res Clin Rheumatol. 2008;22:913–22.

    PubMed  CAS  Google Scholar 

  32. Prince MI, Ducker SJ, James OF. Case–control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59:508–12.

    PubMed  CAS  Google Scholar 

  33. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–202.

    PubMed  Google Scholar 

  34. Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, De Roos AJ. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun. 2012;39:259–71.

    PubMed  Google Scholar 

  35. Medsger Jr TA. Epidemiology of systemic sclerosis. Clin Dermatol. 1994;12:207–16.

    PubMed  Google Scholar 

  36. Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol. 2011;2011:976427.

    PubMed  Google Scholar 

  37. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, Burroughs AK. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388–94.

    PubMed  CAS  Google Scholar 

  38. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. 2003;18:1118–28.

    PubMed  CAS  Google Scholar 

  39. Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:1397–401.

    PubMed  Google Scholar 

  40. Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther. 2011;18:375–81.

    PubMed  Google Scholar 

  41. Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology. 2012;56:1409–17.

    PubMed  Google Scholar 

  42. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev. 2005;4:137–43.

    PubMed  CAS  Google Scholar 

  43. Melum E, Franke A, Schramm C, Weismuller TJ, Gotthardt DN, Offner FA, Juran BD, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17–9.

    PubMed  CAS  Google Scholar 

  44. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9.

    PubMed  Google Scholar 

  45. Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.

    PubMed  Google Scholar 

  46. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl. 2010;16:1324–30.

    PubMed  Google Scholar 

  47. Dobric S, Popovic D, Nikolic M, Andrejevic S, Spuran M, Bonaci-Nikolic B. Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis. Clin Chem Lab Med. 2012;50:503–9.

    CAS  Google Scholar 

  48. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep. 2006;8:75–82.

    PubMed  Google Scholar 

  49. Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Haba R, et al. Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol. 2012;26:125–9.

    PubMed  Google Scholar 

  50. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107–14.

    PubMed  Google Scholar 

  51. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, Reitsma JB, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51:562–6.

    PubMed  CAS  Google Scholar 

  52. Gubergrits NB. Primary sclerosing cholangitis: a clinical case. Dig Dis. 2009;27:522–5.

    PubMed  Google Scholar 

  53. Van Steenbergen W, De Goede E, Emonds MP, Reinders J, Tilanus M, Fevery J. Primary sclerosing cholangitis in two brothers: report of a family with special emphasis on molecular HLA and MICA genotyping. Eur J Gastroenterol Hepatol. 2005;17:767–71.

    PubMed  Google Scholar 

  54. Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005;42:252–6.

    PubMed  Google Scholar 

  55. Quigley EM, LaRusso NF, Ludwig J, MacSween RN, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1983;85:1160–5.

    PubMed  CAS  Google Scholar 

  56. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008;6:939–43.

    PubMed  Google Scholar 

  57. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82:373–84.

    CAS  Google Scholar 

  58. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, Lindor KD. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000;32:182–7.

    PubMed  CAS  Google Scholar 

  59. Karlsen TH, Kaser A. Deciphering the genetic predisposition to primary sclerosing cholangitis. Semin Liver Dis. 2011;31:188–207.

    PubMed  CAS  Google Scholar 

  60. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology. 2013;58(3):1074–83.

    PubMed  CAS  Google Scholar 

  61. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, Laerdahl JK, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57:366–75.

    PubMed  CAS  Google Scholar 

  62. Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology. 2006;43:525–31.

    PubMed  Google Scholar 

  63. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31–9.

    PubMed  CAS  Google Scholar 

  64. Miao XP, Sun XN, Wei H, Ouyang Q. Crohn’s disease and primary sclerosing cholangitis: a case report and review of the literature. Intern Med. 2012;51:2077–81.

    PubMed  Google Scholar 

  65. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–7.

    PubMed  Google Scholar 

  66. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64.

    PubMed  Google Scholar 

  67. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, Koch A. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140:180–8.

    PubMed  Google Scholar 

  68. Strassburg CP. Autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2010;24:667–82.

    PubMed  CAS  Google Scholar 

  69. Guindi M. Histology of autoimmune hepatitis and its variants. Clin Liver Dis. 2010;14:577–90.

    PubMed  Google Scholar 

  70. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N, Shimoda S, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics. 2011;6:95–102.

    PubMed  CAS  Google Scholar 

  71. Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis. 2009;29:254–61.

    PubMed  Google Scholar 

  72. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun. 2013;41:126–39.

    PubMed  CAS  Google Scholar 

  73. Malekzadeh Z, Haghazali S, Sepanlou SG, Vahedi H, Merat S, Sotoudeh M, Nasseri-Moghaddam S, et al. Clinical features and long term outcome of 102 treated autoimmune hepatitis patients. Hepat Mon. 2012;12:92–9.

    PubMed  Google Scholar 

  74. Yoshida O, Abe M, Furukawa S, Murata Y, Hamada M, Hiasa Y, Matsuura B, et al. A familial case of autoimmune hepatitis. Intern Med. 2009;48:315–9.

    PubMed  Google Scholar 

  75. Nolte W, Polzien F, Sattler B, Ramadori G, Hartmann H. Recurrent episodes of acute hepatitis associated with LKM-1 (cytochrome P450 2D6) antibodies in identical twin brothers. J Hepatol. 1995;23:734–9.

    PubMed  CAS  Google Scholar 

  76. Lankisch TO, Mourier O, Sokal EM, Habes D, Lacaille F, Bridoux-Henno L, Hermeziu B, et al. AIRE gene analysis in children with autoimmune hepatitis type I or II. J Pediatr Gastroenterol Nutr. 2009;48:498–500.

    PubMed  CAS  Google Scholar 

  77. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology. 2001;33:1047–52.

    PubMed  CAS  Google Scholar 

  78. Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int. 2010;4:475–93.

    PubMed  Google Scholar 

  79. Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn’s disease: the index case. Dig Dis Sci. 2011;56:3386–8.

    PubMed  Google Scholar 

  80. Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. BioDrugs. 2010;24 Suppl 1:25–7.

    PubMed  Google Scholar 

  81. Fujii K, Rokutanda R, Osugi Y, Koyama Y, Ota T. Adult-onset Still’s disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med. 2012;51:1125–8.

    PubMed  CAS  Google Scholar 

  82. Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, Muratori L, Quarneti C, et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012;24:531–4.

    PubMed  Google Scholar 

  83. Wan DW, Marks K, Yantiss RK, Talal AH. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS. 2009;23:407–13.

    PubMed  Google Scholar 

  84. Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol. 2012;2012:987471.

    PubMed  Google Scholar 

  85. Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, Tatar G, et al. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol. 2013;48(4):504–8.

    PubMed  Google Scholar 

  86. Manns MP, Strassburg CP. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011;29:411–5.

    PubMed  Google Scholar 

  87. Tan CB, Rashid S, Rajan D, Gebre W, Mustacchia P. Hepatic sarcoidosis presenting as portal hypertension and liver cirrhosis: case report and review of the literature. Case Rep Gastroenterol. 2012;6:183–9.

    PubMed  Google Scholar 

  88. Farouj NE, Cadranel JF, Mofredj A, Jouannaud V, Lahmiri M, Lann PL, Cazier A. Ductopenia related liver sarcoidosis. World J Hepatol. 2011;3:170–4.

    PubMed  Google Scholar 

  89. Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol. 2002;35:345–9.

    PubMed  Google Scholar 

  90. Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjogren’s syndrome: a retrospective review. BMC Gastroenterol. 2002;2:21.

    PubMed  Google Scholar 

  91. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 2002;123:1031–43.

    PubMed  CAS  Google Scholar 

  92. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187–94.

    PubMed  CAS  Google Scholar 

  93. Matsumoto T, Yoshimine T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, Hoshi T. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum pathol. 1992;23:1151–8.

    PubMed  CAS  Google Scholar 

  94. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35:2159–64.

    PubMed  CAS  Google Scholar 

  95. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol. 2009;31:421–35.

    PubMed  CAS  Google Scholar 

  96. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology. 2007;46:1641–7.

    PubMed  CAS  Google Scholar 

  97. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–40.

    PubMed  Google Scholar 

  98. Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME. Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol. 1997;36:210–3.

    PubMed  CAS  Google Scholar 

  99. Andres E, Locatelli F, Pflumio F, Marcellin L. Liver biopsy is not useful in the diagnosis of adult Still’s disease. QJM. 2001;94:568–9.

    PubMed  CAS  Google Scholar 

  100. von Knorring J, Wassatjerna C. Liver involvement in polymyalgia rheumatica. Scand J Rheumatol. 1976;5:197–204.

    Google Scholar 

  101. Rodriguez-Valverde V, Sarabia JM, Gonzalez-Gay MA, Figueroa M, Armona J, Blanco R, Fernandez-Sueiro JL, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med. 1997;102:331–6.

    PubMed  CAS  Google Scholar 

  102. Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, Sato N, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366–73.

    PubMed  CAS  Google Scholar 

  103. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J. Behcet’s disease—a contemporary review. J Autoimmun. 2009;32:178–88.

    PubMed  CAS  Google Scholar 

  104. Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, Poterucha JJ, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94.

    PubMed  Google Scholar 

  105. Fix OK, Damon LE, Bass NM. Amyloidosis localized to the liver. Clin Gastroenterol Hepatol. 2007;5:e7.

    PubMed  Google Scholar 

  106. Efe C, Ozaslan E, Nasiroglu N, Tunca H, Purnak T, Altiparmak E. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci. 2010;55:2417–21.

    PubMed  Google Scholar 

  107. Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM. Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren’s syndrome. J Rheumatol. 2008;35:2012–6.

    PubMed  Google Scholar 

  108. Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjogren’s syndrome. J Hepatol. 1994;20:354–8.

    PubMed  CAS  Google Scholar 

  109. Schlenker C, Halterman T, Kowdley KV. Rheumatologic disease and the liver. Clin Liver Dis. 2011;15:153–64.

    PubMed  Google Scholar 

  110. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, Manek N, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36:2250–6.

    PubMed  Google Scholar 

  111. Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Intern Med. 2000;39:451–6.

    PubMed  CAS  Google Scholar 

  112. Hamdouch K, Rodriguez C, Perez-Venegas J, Rodriguez I, Astola A, Ortiz M, Yen TJ, et al. Anti-CENPI autoantibodies in scleroderma patients with features of autoimmune liver diseases. Clin Chim Acta. 2011;412:2267–71.

    PubMed  CAS  Google Scholar 

  113. Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Worns M, Lohse AW, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44:208–13.

    PubMed  CAS  Google Scholar 

  114. Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, Atzeni F, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev. 2009;8:260–5.

    PubMed  CAS  Google Scholar 

  115. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:266–73.

    PubMed  CAS  Google Scholar 

  116. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    PubMed  CAS  Google Scholar 

  117. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39.

    CAS  Google Scholar 

  118. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    PubMed  Google Scholar 

  119. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

    PubMed  CAS  Google Scholar 

  120. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:925–32.

    PubMed  Google Scholar 

  121. Nunes J, Marinho RT, Fonseca JE, Pereira da Silva JA, Velosa J. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice. Acta Reumatol Port. 2011;36:110–8.

    PubMed  Google Scholar 

  122. Lledo JL, Fernandez C, Gutierrez ML, Ocana S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol. 2011;17:1563–8.

    PubMed  Google Scholar 

  123. Radner H, Ramiro S, van der Heijde DM, Landewe R, Buchbinder R, Aletaha D. How do gastrointestinal or liver comorbidities influence the choice of pain treatment in inflammatory arthritis? A Cochrane systematic review. J Rheumatol Suppl. 2012;90:74–80.

    PubMed  Google Scholar 

  124. Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol—a randomized study. Aliment Pharmacol Ther. 2010;32:478–86.

    PubMed  CAS  Google Scholar 

  125. Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010;12:R143.

    PubMed  Google Scholar 

  126. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Annals Rheum Dis. 2010;69:1612–7.

    CAS  Google Scholar 

  127. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? Autoimmun Rev. 2013;12:337–9.

    PubMed  CAS  Google Scholar 

  128. Mahamid M, Mader R, Safadi R. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol. 2011;3:39–43.

    PubMed  CAS  Google Scholar 

  129. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51 Suppl 5:v38–47.

    PubMed  CAS  Google Scholar 

  130. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–7.

    PubMed  Google Scholar 

  131. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–44.

    PubMed  Google Scholar 

  132. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.

    PubMed  Google Scholar 

  133. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:1929–30.

    PubMed  Google Scholar 

  134. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus Jr EV, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–9.

    PubMed  Google Scholar 

  135. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–7.

    PubMed  Google Scholar 

  136. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17:908–13.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, 20089, Milan, Italy

    Carlo Selmi M.D., Ph.D., Angela Ceribelli & Maria De Santis

  2. BIOMETRA Department, University of Milan, Milan, Italy

    Carlo Selmi M.D., Ph.D., Angela Ceribelli & Maria De Santis

  3. Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA, USA

    Carlo Selmi M.D., Ph.D.

  4. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Cecilia B. Chighizola & Pier Luigi Meroni

  5. Division of Rheumatology, Istituto G. Pini, Milan, Italy

    Cecilia B. Chighizola & Pier Luigi Meroni

  6. Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

    Renqian Zhong

Authors
  1. Carlo Selmi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cecilia B. Chighizola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Ceribelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria De Santis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pier Luigi Meroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renqian Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Selmi M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA

    M. Eric Gershwin

  2. Medicine and Surgery, Baylor College of Medicine, Houston, Texas, USA

    John M. Vierling

  3. Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany

    Michael P. Manns

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Selmi, C., Chighizola, C.B., Ceribelli, A., De Santis, M., Meroni, P.L., Zhong, R. (2014). The Geoepidemiology of Autoimmune Liver Disease. In: Gershwin, M., Vierling, J., Manns, M. (eds) Liver Immunology. Springer, Cham. https://doi.org/10.1007/978-3-319-02096-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-02096-9_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-02095-2

  • Online ISBN: 978-3-319-02096-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation